Lates News

According to the public WeChat account of China Biotech, the domestic first quadrivalent human papillomavirus vaccine (Hansen's yeast) (Ivalin) independently developed by Chengdu Biologics Institute of China Biotech Group and the National Engineering Research Center for Novel Vaccine of China Biotech Research Institute has been officially approved by the National Medical Products Administration for marketing. This vaccine uses the same yeast expression system as the international mainstream to prepare the domestically produced bivalent vaccine, adding protection against HPV6 and HPV11 persistent infections that cause genital warts on the basis of preventing high-risk HPV16 and HPV18 persistent infections that cause cervical cancer, filling the void in protection against low-risk HPV infections related to genital warts by the domestically produced bivalent vaccine.